Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer

作者：Chongyu Wang, Pinchao Fan, Qingqing Wang · 发表于：Cancer Treatment Reviews · 年份：2024 · DOI：10.1016/j.ctrv.2024.102819 · 被引用次数：10 · 研究领域：Chemotherapy-induced cardiotoxicity and mitigation、Cancer Treatment and Pharmacology、Cancer-related cognitive impairment studies

Defined as scarce expression of hormone receptors and human epidermal growth factor receptor 2, triple-negative breast cancer (TNBC) is labeled as the most heterogeneous subtype of breast cancer with poorest prognosis. Despite rapid advancements in precise subtyping and tailored therapeutics, the ensuing cancer therapy-related cardiovascular toxicity (CTR-CVT) could exert detrimental impacts to TNBC survivors. Nowadays, this interdisciplinary issue is incrementally concerned by cardiologists, oncologists and other pertinent experts, propelling cardio-oncology as a booming field focusing on the whole-course management of cancer patients with potential cardiovascular threats. Here in this review, we initially profile the evolving molecular subtyping and therapeutic landscape of TNBC. Further, we introduce various monitoring approaches of CTR-CVT. In the main body, we elaborate on typical cardiotoxicities ensuing anti-TNBC treatments in detail, ranging from chemotherapy (especially anthracyclines), surgery, anesthetics, radiotherapy to immunotherapy, with future perspectives on promising directions in the era of artificial intelligence and traditional Chinese medicine.